Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study
W. Wolfgang Fleischhacker, Jana Podhorná, Martina Gröschl, et al.
The Lancet Psychiatry (2021) Vol. 8, Iss. 3, pp. 191-201
Closed Access | Times Cited: 101

Showing 1-25 of 101 citing articles:

Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
Robert A. McCutcheon, Richard S.E. Keefe, Philip McGuire
Molecular Psychiatry (2023) Vol. 28, Iss. 5, pp. 1902-1918
Open Access | Times Cited: 315
The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents
Christoph U. Correll, Marco Solmi, Samuele Cortese, et al.
World Psychiatry (2023) Vol. 22, Iss. 1, pp. 48-74
Open Access | Times Cited: 82
New and emerging approaches to treat psychiatric disorders
Katherine W. Scangos, Matthew W. State, Andrew H. Miller, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 317-333
Closed Access | Times Cited: 70
The schizophrenia syndrome, circa 2024: What we know and how that informs its nature
Rajiv Tandon, Henry A. Nasrallah, Schahram Akbarian, et al.
Schizophrenia Research (2023) Vol. 264, pp. 1-28
Open Access | Times Cited: 59
Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018–2022)
Saghir Ali, Jia Zhou
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115476-115476
Open Access | Times Cited: 49
Schizophrenia: from neurochemistry to circuits, symptoms and treatments
Oliver Howes, Bernard R Bukala, Katherine Beck
Nature Reviews Neurology (2023) Vol. 20, Iss. 1, pp. 22-35
Closed Access | Times Cited: 49
Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia
Holger Rosenbrock, Michael Desch, Glen Wunderlich
European Archives of Psychiatry and Clinical Neuroscience (2023) Vol. 273, Iss. 7, pp. 1557-1566
Open Access | Times Cited: 44
Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments
Stephen R. Marder, Daniel Umbricht
Schizophrenia Research (2023) Vol. 258, pp. 71-77
Open Access | Times Cited: 42
Glutamate-Mediated Excitotoxicity in the Pathogenesis and Treatment of Neurodevelopmental and Adult Mental Disorders
Noemi Nicosia, M. Giovenzana, Paulina Misztak, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6521-6521
Open Access | Times Cited: 17
New Drug Treatments for Schizophrenia: A Review of Approaches to Target Circuit Dysfunction
Oliver Howes, Eleanor Dawkins, Maria Lobo, et al.
Biological Psychiatry (2024) Vol. 96, Iss. 8, pp. 638-650
Open Access | Times Cited: 15
Knowing is Half the Battle: The Factors Leading to Efficient Recruitment of Representative Samples in Schizophrenia Research
Joohyun Yoon, Megan Mayer, Tala Berro, et al.
Pharmaceutical Medicine (2025)
Closed Access | Times Cited: 2
Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to Treatment
Daniel C. Javitt
The Annual Review of Pharmacology and Toxicology (2022) Vol. 63, Iss. 1, pp. 119-141
Open Access | Times Cited: 59
New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics
Maria Lobo, Thomas Whitehurst, Stephen Kaar, et al.
Neuroscience & Biobehavioral Reviews (2021) Vol. 132, pp. 324-361
Open Access | Times Cited: 57
Acceptability of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
Antonio Vita, Sergio Barlati, Anna Ceraso, et al.
Psychological Medicine (2022) Vol. 53, Iss. 8, pp. 3661-3671
Open Access | Times Cited: 50
Schizophrenia: One Name, Many Different Manifestations
Justin Faden, Leslie Citrome
Medical Clinics of North America (2022) Vol. 107, Iss. 1, pp. 61-72
Closed Access | Times Cited: 39
Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia
Eric D. Achtyes, Seth C. Hopkins, Nina Dedic, et al.
European Archives of Psychiatry and Clinical Neuroscience (2023) Vol. 273, Iss. 7, pp. 1543-1556
Open Access | Times Cited: 29
New Developments in the Treatment of Schizophrenia: An Expert Roundtable
Joshua T. Kantrowitz, Christoph U. Correll, Rakesh Jain, et al.
The International Journal of Neuropsychopharmacology (2023) Vol. 26, Iss. 5, pp. 322-330
Open Access | Times Cited: 23
The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia
Daniela L. Uliana, João Roberto Lisboa, Felipe V. Gomes, et al.
Biochemical Pharmacology (2024) Vol. 228, pp. 116298-116298
Closed Access | Times Cited: 13
Beyond dopamine: Novel strategies for schizophrenia treatment
Paulina Dudzik, Klaudia Lustyk, Karolina Pytka
Medicinal Research Reviews (2024) Vol. 44, Iss. 5, pp. 2307-2330
Closed Access | Times Cited: 12
Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives
Antonio Vita, Gabriele Nibbio, Sergio Barlati
Schizophrenia Bulletin Open (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 12
INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia
Venkatesha Murthy, Elizabeth Hanson, Nicholas DeMartinis, et al.
Schizophrenia Research (2024) Vol. 270, pp. 249-257
Open Access | Times Cited: 11
Highlights on Fluorine-containing Drugs Approved by U.S. FDA in 2023
Saghir Ali, Andrew A. Bolinger, Jia Zhou
Current Topics in Medicinal Chemistry (2024) Vol. 24, Iss. 10, pp. 843-849
Open Access | Times Cited: 8
Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds
Letizia Biso, Marco Carli, Marco Scarselli, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 85-85
Open Access | Times Cited: 1
Corticolimbic circuitry as a druggable target in schizophrenia spectrum disorders: a narrative review
Abigail Gee, Paola Dazzan, Anthony A. Grace, et al.
Translational Psychiatry (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Towards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia and Other Neuropsychiatric Conditions: Insights From 2 Decades of Clinical Trials
W. P. Horan, Amir H Kalali, Stephen K. Brannan, et al.
Schizophrenia Bulletin (2025)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top